USpace Technology Group Stock (OTC: USPCY)

Latest news for USpace Technology Group (OTC:USPCY) Stock

USpace Technology Group Ltd formerly Hong Kong Aerospace Technology Group Ltd is a commercial aerospace company. Its core business is satellite precision manufacturing, control, and aerospace data services to support regional aerospace commercialization needs. The Group has three reportable operating segments they are EMS business - Smart home devices EMS business-Banking and finance and other devices along with Aerospace business.

USPACE TECHN GRP S/ADR by USPACE TECHNOLOGY GROUP LTD.

USpace Technology Group Ltd

RBC Capital analyst Shagun Singh reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $400 to $425.

News

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Stryker, Raises Price Target to $425

WIIM

ReNew Energy Global shares are trading higher after the company announced it received $7.07 share buyout proposal from a consortium including Masdar, CPP Investments, ADIA and founder Sumant Sinha to acquire the remaining share capital.

RBC Capital analyst Gregory Renza reiterates Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) with a Sector Perform and lowers the price target from $2 to $1.5.

SPRB

RBC Capital Reiterates Sector Perform on Spruce Biosciences, Lowers Price Target to $1.5

Stifel analyst Nathan Jones maintains Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) with a Buy and raises the price target from $360 to $382.

Stifel Maintains Buy on Valmont Industries, Raises Price Target to $382

Wells Fargo analyst James Feldman maintains Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Equal-Weight and lowers the price target from $154 to $135.

Wells Fargo Maintains Equal-Weight on Sun Communities, Lowers Price Target to $135

Shares of Dave &amp; Buster&#8217;s Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) fell over 14% at last check Wednesday, despite reporting <a href="https://www.benzinga.com/24/12/42437664/why-dave-busters-entertainment-stock-is-tumbling-wednesday">downbeat third-quarter results</a>.
<ul>
<li>Truist Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/589dc33d43eaaa000122c591/jake-bartlett">analyst Jake Bartlett</a> downgraded the rating from Buy to Hold, while slashing the price target from $56 to $36.</li>
<li>Benchmark <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5935519f85b07a0001c0bc58/mike-hickey">analyst Mike Hickey</a> maintained a Hold rating on the stock.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Truist Securities: Dave &amp; Buster&#8217;s reported its adjusted EBITDA at $68.3 million. That&#8217;s short of the consensus of $75.8 million. Same-store sales and store-level margins drove the shortfall, Bartlett said. Consolidated same-store sales fell by 7.7%, much worse than consensus of a 5.9% decline, while store-level margins contracted by 160 basis points, he added.
This was the seventh consecutive quarterly sales miss, the analyst stated. The unexpected resignation of CEO Chris Morris, who had devised the turnaround plan, added to the uncertainty around its execution, he noted.
The CEO departure, along with disappointing sales lifts from recent remodels, "shakes our confidence in PLAY&#8217;s sales catalysts," Bartlett further wrote.
Benchmark: Dave &amp; Buster&#8217;s reported disappointing third-quarter results due to challenging macro conditions, "growing pains" from some of the strategic initiatives, and slightly longer-than-expected implementation for some initiatives, Hickey said in a note. Management expressed their frustration around the strategic initiatives not yielding the desired results due to the macro environment, he added.
"The departure of CEO Chris Morris adds an additional friction to executing the second half of PLAY's strategic plan," as he was the "primary architect" of the plan that was launched around 18 months ago, the analyst wrote. Management guided to full year adjusted EBITDA of $500 million to $515 million, below the consensus estimate of $525 million, he further stated.
Price Action: Shares of Dave &amp; Buster&#8217;s declined by 14.04% to $31.64 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/content/41005667/3-beaten-up-experiential-stocks-to-cash-in-on-a-good-time">3 Beaten Up Experiential Stocks to Cash in on a Good Time</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Downgrades

Movers

Trading Ideas

PLAY

Dave & Buster's Shares Tank Following Earnings Report, Analysts Say CEO Exit Clouds Turnaround Prospects

Stifel analyst Jim Duffy maintains Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) with a Buy and raises the price target from $35 to $41.

RVLV

Stifel Maintains Buy on Revolve Gr, Raises Price Target to $41

RBC Capital analyst Luca Issi reiterates Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Outperform and maintains $35 price target.

RGNX

RBC Capital Reiterates Outperform on Regenxbio, Maintains $35 Price Target

Wells Fargo analyst Michael Sison maintains Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) with a Overweight and lowers the price target from $95 to $90.

Wells Fargo Maintains Overweight on Ashland, Lowers Price Target to $90

Stifel analyst Stanley Elliott maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Buy and raises the price target from $343 to $374.

Stifel Maintains Buy on Quanta Services, Raises Price Target to $374

Wells Fargo analyst Sam Reid maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and lowers the price target from $232 to $220.

FERG

Wells Fargo Maintains Overweight on Ferguson Enterprises, Lowers Price Target to $220

Stifel analyst Nathan Jones maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Buy and raises the price target from $115 to $126.

Stifel Maintains Buy on Pentair, Raises Price Target to $126

RBC Capital analyst Steven Shemesh maintains Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Outperform and raises the price target from $120 to $130.

OLLI

RBC Capital Maintains Outperform on Ollie's Bargain Outlet, Raises Price Target to $130

Wells Fargo analyst Matthew Akers maintains TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) with a Equal-Weight and lowers the price target from $1500 to $1375.

Wells Fargo Maintains Equal-Weight on TransDigm Gr, Lowers Price Target to $1375

Stifel analyst Jim Duffy maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $60 to $66.

ONON

Stifel Maintains Buy on On Holding, Raises Price Target to $66

Stifel analyst Brian Brophy maintains MYR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) with a Buy and raises the price target from $153 to $172.

MYRG

Stifel Maintains Buy on MYR Group, Raises Price Target to $172

RBC Capital analyst Ken Herbert maintains MDA Space (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MDA#TSX">MDA</a>) with a Outperform and raises the price target from C$30 to C$35.

TSX:MDA

RBC Capital Maintains Outperform on MDA Space, Raises Price Target to C$35

Wells Fargo analyst Matthew Akers maintains Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Equal-Weight and raises the price target from $13.5 to $22.

RKLB

Wells Fargo Maintains Equal-Weight on Rocket Lab USA, Raises Price Target to $22

Stifel analyst Michael Hoffman maintains Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>) with a Buy and lowers the price target from $41 to $38.

Stifel Maintains Buy on Montrose Environmental Gr, Lowers Price Target to $38

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 1% on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.02% to 44,257.30 while the NASDAQ rose 1.27% to 19,936.66. The S&amp;P 500 also rose, gaining, 0.64% to 6,073.33.
Check This Out: <a href="https://www.benzinga.com/24/12/42432935/top-3-health-care-stocks-that-may-collapse-this-quarter">Top 3 Health Care Stocks That May Collapse This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 2.4% on Wednesday.
In trading on Wednesday, health care shares fell by 1.1%.
Top Headline
The Consumer Price Index rose by 2.7% year-over-year in November 2024, exceeding October's 2.6% reading and matching analyst estimates of 2.7%, according to TradingEconomics. This marks the second consecutive increase in annual inflation — a trend not seen since April.
On a monthly basis, the CPI jumped 0.3%, accelerating from October&#8217;s 0.2% gain and matching expectations of a 0.3% rise, official data released Wednesday showed.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares shot up 124% to $10.32 after the company announced results from its Phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients.</li>
<li>Shares of AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) got a boost, surging 109% to $2.07 after the company announced the development and deployment of its proprietary low-noise cryogenic High Electron Mobility Transistor amplifiers.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares were also up, gaining 98% to $1.1400.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares dropped 74% to $0.3356 after the company announced it is seeking strategic options for the Iopofosine I 131 late-stage clinical program. This will impact all departments and result in an immediate 60% headcount reduction.</li>
<li>Shares of Q32 Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) were down 68% to $7.91 after the company announced that while its SIGNAL-AD Phase 2a clinical trial in atopic dermatitis showed promising findings in Part A, it did not meet the primary endpoint in Part B.</li>
<li>TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) was down, falling 42% to $0.1758.</li>
</ul>
Commodities In commodity news, oil traded up 1.2% to $69.38 while gold traded up 1.3% at $2,753.20.
Silver traded up 1% to $33.075 on Tuesday, while copper fell 0.3% to $4.2615.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.23%, Germany's DAX rose 0.17% and France's CAC 40 gained 0.31%. Spain's IBEX 35 Index fell 1.31%, while London's FTSE 100 rose 0.23%.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 gaining 0.01%, Hong Kong's Hang Seng Index falling 0.77%, China's Shanghai Composite Index gaining 0.29% and India's BSE Sensex gaining 0.02%.
Economics
<ul>
<li>The Consumer Price Index rose by 2.7% year-over-year in November 2024, exceeding October's 2.6% reading and matching analyst estimates of 2.7%, according to TradingEconomics. This marks the second consecutive increase in annual inflation — a trend not seen since April.</li>
<li>On a monthly basis, the CPI jumped 0.3%, accelerating from October&#8217;s 0.2% gain and matching expectations of a 0.3% rise, official data released Wednesday showed.</li>
<li>U.S. crude inventories declined by 1.425 million barrels in the latest week, compared to market estimates of a 1.1 million-barrel decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a></li>
</ul>

Comments

USpace Technology Group

News

Latest news for USpace Technology Group (OTC:USPCY) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga